A New JAMA Trial on Antidepressant Pharmacogenetics: What It Means for PGx

A new randomized clinical trial in JAMA Network Open looked at a practical question many patients and clinicians care about: can pharmacogenetic-guided prescribing help people with depression do better on selective serotonin reuptake inhibitors, commonly called SSRIs?

The answer is nuanced, and that is exactly why the study is worth paying attention to.

In the trial, genotype-guided SSRI prescribing did not significantly improve depression symptom scores at 3 months compared with usual care among patients with actionable CYP2D6 or CYP2C19 results. But by 6 months, remission rates were higher in the genotype-guided group.

That makes this a very PGx kind of result: not magic, not instant, but potentially useful when applied to the right medication, the right gene, and the right clinical decision.

First, a safety note

Pharmacogenetics (PGx) is educational and clinical decision-support information. It should not be used to stop, start, or change the dose of an antidepressant without a qualified healthcare professional.

Depression treatment decisions should account for symptoms, diagnosis, medication history, dose, side effects, interactions, psychotherapy, medical conditions, safety concerns, and patient preferences. PGx can be one useful piece of that bigger picture.

What the new study tested

The study was called the ADOPT PGx Depression trial. It was a pragmatic randomized clinical trial conducted at primary care, psychiatry, and family medicine clinics across the US between August 2021 and April 2024. Patients were 8 years or older and had experienced depression for at least 3 months.

Researchers randomized patients to either:

  1. Genotype-guided SSRI prescribing, where CYP2D6 and CYP2C19 results were returned through clinical decision support in the electronic health record
  2. Usual care, where clinicians treated depression without immediate PGx-guided SSRI recommendations

The trial focused on CYP2D6 and CYP2C19 because these genes have established relevance to SSRI metabolism. It also accounted for CYP2D6 “phenoconversion,” which means that certain medications can make a person function more like a slower CYP2D6 metabolizer than their genotype alone would predict.

That last point matters. Genetics is stable, but medication response is not only genetics. A strong CYP2D6 inhibitor can temporarily change how CYP2D6 behaves in real life.

The big result: no clear 3-month symptom improvement, but higher 6-month remission

The primary outcome was change in PROMIS depression T score at 3 months among patients with an actionable phenotype. In that group, symptom improvement was similar:

So, if the question is, “Did PGx-guided SSRI prescribing clearly improve depression scores by 3 months?” the answer in this trial was no.

But the 6-month remission findings were more encouraging:

The authors concluded that genotype-guided SSRI prescribing was not associated with better symptom control at 3 months, but was associated with higher remission rates at 6 months among patients with actionable phenotypes. They described this as a possible longer-term benefit that deserves further study.

That is the right level of confidence: promising, but not overhyped.

Why “actionable phenotype” is the key phrase

One of the most important details in the study is that not everyone had a result expected to change prescribing.

Among successfully genotyped patients, 692 of 1425, or 48.6%, had an actionable CYP2C19 or CYP2D6 phenotype.

That means almost half of patients had a gene result where published clinical guidance could point toward a different dose, different medication, or more careful selection. The other half did not have a PGx result expected to change SSRI prescribing based on the study’s criteria.

This is a practical lesson for interpreting any PGx report:

A genetic result is not useful because it is interesting. It is useful when it connects to a medication decision.

A simple way to think about CYP2C19, CYP2D6, and antidepressants

Many antidepressants are processed by liver enzymes. CYP2C19 and CYP2D6 are two of the most important enzymes for several commonly used antidepressants.

In plain language:

This is why PGx works best when it is interpreted together with the medication list. A genotype is the starting point. The active medication list shows what is happening now.

What this study does not mean

It does not mean PGx is useless for antidepressants.

The trial found improved medication and pharmacogenetic phenotype concordance at 3 months, meaning patients in the genotype-guided group were more likely to be on an SSRI and dose that matched their PGx profile. The concordance rate was 84.5% in the genotype-guided group vs 74.3% in usual care.

It also does not mean PGx works immediately.

Depression outcomes can take time to change. Even when a medication choice is improved, patients may need dose adjustments, follow-up visits, psychotherapy support, adherence changes, or time on a better-matched regimen before remission differences appear.

It does not mean every antidepressant has a clear gene-based answer.

CPIC’s 2023 antidepressant guideline includes actionable recommendations for several antidepressant-gene pairs, including citalopram and escitalopram with CYP2C19, paroxetine and fluvoxamine with CYP2D6, sertraline with CYP2C19 and CYP2B6, and venlafaxine and vortioxetine with CYP2D6. It also notes that some studied genes and drugs do not currently have actionable recommendations.

That is why PGx should be treated as targeted guidance, not a universal antidepressant ranking system.

What this study means for patients

For patients, the most practical takeaway is this:

If you have had repeated antidepressant side effects, partial response, nonresponse, or unusual dose sensitivity, PGx may help explain part of the pattern, especially for medications with CYP2C19 or CYP2D6 guidance.

How this can feel in real life:

PGx will not explain every case of antidepressant nonresponse. But when a gene-drug pair is clinically supported, it can help make the next conversation more specific.

What this study means for clinicians

For clinicians, this study reinforces a balanced approach.

PGx may be most useful when:

  1. The patient is taking or considering a medication with established PGx guidance.
  2. The patient has an actionable phenotype.
  3. The result is available at the point of prescribing.
  4. The recommendation is integrated into a clinical workflow.
  5. Drug interactions, especially CYP2D6 inhibitors, are reviewed at the same time.

The ADOPT PGx trial used peer-reviewed guideline-based recommendations and FDA sources rather than an opaque commercial algorithm. The authors specifically contrasted this with concerns about unvalidated pharmacogenomic tools that could delay better medication choices.

That distinction matters. Good PGx is not just “more genes.” Good PGx is transparent, medication-specific, and tied to evidence-based recommendations.

How Gene2Rx fits into the conversation

Gene2Rx is designed to make pharmacogenetic insights easier to access, especially for people who already have consumer genetic data from supported services.

A Gene2Rx report can help identify medications where your genetic profile may suggest a typical or atypical response, using sources such as CPIC and FDA guidance where available. Gene2Rx reports are intended as a starting point for discussion with a healthcare professional, not as a clinical diagnosis or a substitute for medical advice.

For antidepressants specifically, this kind of report can help you ask better questions, such as:

The goal is not to replace your clinician’s judgment. The goal is to bring a clearer, evidence-based medication response signal into the conversation.

What to do next if you are taking an antidepressant

A practical next step is to write down:

  1. Which antidepressants you have tried
  2. The dose and how long you took each one
  3. Whether the problem was lack of benefit, side effects, or both
  4. Other prescriptions, over-the-counter medications, supplements, nicotine, caffeine, alcohol, or cannabis use
  5. Any prior genetic data or PGx report you already have

Then bring that summary to your clinician.

If you have supported genetic data, Gene2Rx can help you quickly explore whether known PGx guidance may apply to your current or future medications. For high-stakes treatment decisions, clinical-grade confirmatory testing and clinician oversight may be appropriate.

The bottom line

This new JAMA Network Open trial is not a simple “PGx works” or “PGx does not work” story.

It is more useful than that.

Genotype-guided SSRI prescribing did not produce a clear symptom-score advantage at 3 months, but patients with actionable CYP2D6 or CYP2C19 results had higher remission rates at 6 months. That suggests PGx may be more of a long-game tool than an instant fix.

For patients, the message is practical: PGx will not explain everything, but it may help explain why certain antidepressants feel too strong, too weak, or hard to tolerate.

For clinicians, the message is equally practical: use PGx where the evidence is strongest, interpret it alongside drug interactions and clinical context, and focus on gene-drug pairs with transparent guidance.

Medication response should not be pure trial and error. PGx does not remove all uncertainty, but when it applies, it can make the next step more informed.

Sources